AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Show more
Location: 1 Francis Crick Avenue, Cambridge, CB2 0AA, United Kingdom | Website: https://www.astrazeneca.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
215.2B
52 Wk Range
$61.24 - $87.68
Previous Close
$69.26
Open
$69.59
Volume
2,992,178
Day Range
$68.66 - $69.61
Enterprise Value
134.7B
Cash
5.395B
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
17.08%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Enhertu Details Cancer, Breast cancer | Approved Update | |
Imfinzi Details Cancer, Bladder cancer | Approved Update | |
Approved Update | ||
Calquence (acalabrutinib) Details Cancer, Blood cancer, Chronic lymphocytic leukemia, Small lymphocytic lymphoma | Approved Update | |
Imfinzi (durvalumab) +Imjudo (tremelimumab) +platinum-based chemotherapy Details Cancer, Non-small cell lung carcinoma, Lung cancer | Approved Update | |
Calquence (acalabrutinib) w/ bendamustine and rituximab Details Cancer, Blood cancer, Mantle cell lymphoma | Approved Quarterly sales | |
Lynparza w/ abiraterone and prednisone or prednisolone Details Solid tumor/s, Cancer, Castration-resistant prostate cancer | Approved Quarterly sales | |
Ultomiris Details Rare diseases, Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome, Neuromyelitis optica spectrum disorder (NMOSD) | Approved Quarterly sales | |
Datroway (datopotamab deruxtecan) Details Cancer, Breast cancer | Approved Quarterly sales | |
Imfinzi + chemotherapy (as neoadjuvant treatment) Details Cancer, Non-small cell lung carcinoma, Lung cancer | Approved Quarterly sales | |
Farxiga Details Type 2 diabetes | Approved Quarterly sales | |
Imfinzi + Lynparza Details Cancer, Solid tumor/s, Endometrial cancer | Approved Quarterly sales | |
Soliris (eculizumab) Details Myasthenia gravis, Paroxysmal nocturnal hemoglobinuria , Atypical haemolytic uraemic syndrome | Approved Quarterly sales | |
DATROWAY® (datopotamab deruxtecan) Details Non-small cell lung carcinoma | Approved Quarterly sales | |
Tagrisso Details Non-small cell lung carcinoma, Cancer, Lung cancer | Approved Quarterly sales | |
Truqap (Capivasertib) + Faslodex (fulvestrant) Details Breast cancer, Cancer | Approved Quarterly sales | |
Imfinzi (durvalumab) Details Lung cancer, Cancer, Small cell lung cancer | Approved Quarterly sales | |
Forxiga (dapagliflozin) Details Heart failure | Approved Quarterly sales | |
Enhertu Details Cancer, Solid tumor/s | Approved Quarterly sales | |
Tagrisso + chemotherapy Details Lung cancer, Cancer, EGFR-mutated advanced lung cancer | Approved Quarterly sales | |
Voydeya (Danicopan) Details Paroxysmal nocturnal hemoglobinuria | Approved Quarterly sales | |
Tezspire (tezepelumab) Details no known indication | Approved Quarterly sales | |
Approved Quarterly sales | ||
Beyfortus (Nirsevimab) Details Respiratory syncytial virus, Respiratory virus, Viral infection | Approved Quarterly sales | |
Fasenra Details Coronary Microvascular Dysfunction, Eosinophilic granulomatosis with polyangiitis | Approved Quarterly sales | |
Andexxa (andexanet alfa) Details Intracranial haemorrhage | PDUFA Approval decision | |
Blenrep combinations (BVd & BPd) Details Multiple myeloma | PDUFA Approval decision | |
Blenrep combinations (BVd & BPd) Details Multiple myeloma | PDUFA Adcomm | |
NDA Submission | ||
Orpathys + Tagrisso Details Cancer, Solid tumor/s | Phase 3 Data readout | |
Calquence (acalabrutinib) + venetoclax +/- obinutuzumab Details Cancer, Blood cancer, Chronic lymphocytic leukemia | Phase 3 Data readout | |
Saphnelo Details Idiopathic pulmonary fibrosis | Phase 3 Data readout | |
Breztri Aerosphere Details Asthma | Phase 3 Data readout | |
ENHERTU + rilvegostomig or pembrolizumab Details Endometrial cancer | Phase 3 Data readout | |
LYNPARZA Details Cancer, Solid tumor/s, Ovarian cancer | Phase 3 Data readout | |
Tozorakimab Details Respiratory conditions, Acute respiratory distress syndrome, Lung disease | Phase 3 Data readout | |
Imfinzi (mono/combo) Details Cancer, Liver cancer | Phase 3 Data readout | |
Imfinzi (durvalumab) Details Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 3 Data readout | |
Fasenra Details Chronic rhinosinusitis with nasal polyps | Phase 3 Data readout | |
LYNPARZA Details Cancer, Solid tumor/s, Ovarian cancer | Phase 3 Data readout | |
Tezspire (tezepelumab) Details Chronic rhinosinusitis with nasal polyps | Phase 3 Data readout | |
Anselamimab (CAEL-101) Details Amyloid light chain amyloidosis | Phase 3 Data readout | |
Phase 3 Data readout | ||
Tagrisso Details Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 3 Data readout | |
Koselugo (selumetinib, MEK inhibitor) Details Cancer, Solid tumor/s, Neurofibromatosis type 1 | Phase 3 Data readout | |
Fasenra Details Coronary Microvascular Dysfunction | Phase 3 Update | |
Farxiga Details Acute myocardial infarction | Phase 3 Update | |
ENHERTU Details Gastroesophageal Junction (GEJ) Cancer | Phase 3 Update | |
Camizestrant + CDK 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) vs AI + CDK 4/6 inhibitor Details Advanced HR-positive breast cancer | Phase 3 Update | |
Capivasertib Details Breast cancer, Cancer, Triple-negative breast cancer | Phase 3 Update | |
roxadustat Details Myelodysplastic syndrome, Anemia | Phase 3 Update | |
Imfinzi comb w/ chemotherapy Details Cancer, Biliary Tract Cancer | Phase 3 Update | |
Sipavibart (AZD3152) Details COVID-19 | Phase 3 Update | |
Imfinzi (durvalumab) + SoC (FLOT) chemotherapy Details Cancer, Gastroesophageal junction tumors, Gastric cancer | Phase 3 Update | |
Phase 3 Update | ||
FPI-2265 Details Prostate cancer, Cancer | Phase 2/3 Update | |
balcinrenone/dapagliflozin (MR modulator + SGLT2 inhibitor) Details Cancer, Chronic kidney disease, Heart failure | Phase 2b Data readout | |
AZD0780 (oral PCSK9 inhibitor) Details Dyslipidemia | Phase 2b Update | |
Baxdrostat Details Chronic kidney disease | Phase 2 Data readout | |
Baxdrostat Details Pulmonary hypertension | Phase 2 Data readout | |
Tozorakimab (IL-33 ligand mAb) Details Diabetic Kidney Disease | Phase 2 Data readout | |
Anselamimab (CAEL-101) Details Amyloid light chain amyloidosis | Phase 2 Data readout | |
Enhertu Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
DATROWAY® (datopotamab deruxtecan) Details Resectable, early-stage (stage IIA-IIIB) NSCLC | Phase 2 Update | |
Baxdrostat Details Primary aldosteronism | Phase 2 Update | |
DATROWAY® (datopotamab deruxtecan) Details Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s, Triple-negative breast cancer | Phase 1/2 Data readout | |
LB-001 Details Methylmalonic acidemia, Genetic disorder, Rare genetic disease | Phase 1/2 Interim update | |
Phase 1b Update | ||
ECC5004 Details Obesity, Type 2 diabetes | Phase 1 Data readout | |
DATROWAY® (datopotamab deruxtecan) Details Solid tumor/s | Phase 1 Data readout | |
FPI-2059 Details Solid tumor/s, Cancer | Phase 1 Update | |
DATROWAY® (datopotamab deruxtecan) + KEYTRUDA® (pembrolizumab) Details Non-small cell lung carcinoma, Lung cancer, Cancer | Phase 1 Update | |
FPI-1434 (targeted alpha radioimmunoconjugate) Details Solid tumor/s, Cancer | Phase 1 Update | |
FPI-2068 Details Solid tumor/s, Cancer | Phase 1 Update |